Skip to content

2APharma

Biopharmaceutical company

  • Home
  • ABOUT US
  • VACCINE PLATFORM
  • PIPELINE
    • OVERVIEW
    • 2AP01
    • 2AP02
    • 2AP03
    • 2AP05
    • 2AP07
  • NEWS
  • CONTACT US

June 4, 2020

2AP03

OVERVIEW:

  • High anti-IgE auto-antibody response in non-human primates
  • Highly efficacious in blocking histamine release
  • 2A Pharma’s B-cell epitope vaccine candidate, AAVLP-IgE, has in laboratory tests with non-human primates been shown to be effective at inducing anti-IgE autoantibodies. This gives the potential for a vaccine with similar benefits to approved anti‐human immunoglobulin E (IgE) antibody treatments of, for example, asthma, nut allergy etc. Currently, the potential of a bivalent AAVLP-IgE vaccine is being investigated.

    Back

    Denmark

    2A Pharma ApS
    Niels Jernes Vej 10
    9220 Aalborg Øst
    Denmark

    CVR No.: 3939 1597
    VAT No.: DK 3939 1597

    Sweden

    2A Pharma AB
    Södergatan 3
    211 34 Malmö
    Sweden

    Registration No.: 559090-2788
    VAT No.: SE55 9090 2788 01

    Pipeline

  • 2AP01 HPV
  • 2AP02 Breast Cancer
  • 2AP03 Allergic Diseases
  • 2AP04 Alzheimer's
  • 2AP05 Autoimmune Diseases
  • 2AP06 HIV
  • 2AP07 Head and Neck Cancer
  • Subscribe to our newsletters

    Contact

    +45 7214 6700
    info@2apharma.com